UBS Reiterates Buy Rating on CG Oncology (CGON) as AUA 2026 Abstracts Released
Tweet Send to a Friend
UBS analyst David Dai reiterated a Buy rating and $90.00 price target on CG Oncology (NASDAQ: CGON).The analyst commented, "AUA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
